OncoCyte Corp (OCX) : Mivtachim The Workers Social Insurance Fund Ltd. (under S… added new position in OncoCyte Corp during the most recent quarter end. The investment management firm now holds 571 shares of OncoCyte Corp which is valued at $2,295 , the company said in a statement filed on May 9, 2016 with the SEC.
Other Hedge Funds, Including , Nationwide Fund Advisors reduced its stake in OCX by selling 1 shares or 0.06% in the most recent quarter. The Hedge Fund company now holds 1,684 shares of OCX which is valued at $8,420. Schwab Charles Investment Management Inc sold out all of its stake in OCX during the most recent quarter. The investment firm sold 4,175 shares of OCX which is valued $20,875. Ifp Advisors Inc added OCX to its portfolio by purchasing 1 company shares during the most recent quarter which is valued at $5.
Many Wall Street Analysts have commented on OncoCyte Corp. Lake Street Initiated OncoCyte Corp on Mar 24, 2016 to “Buy”, Price Target of the shares are set at $8.
OncoCyte Corporation (OncoCyte) is engaged in developing non-invasive liquid biopsy diagnostic tests in areas of high unmet need in oncology. The Company’s initial focus is confirmatory diagnostics that are used in conjunction with imaging to confirm initial diagnoses. It also focuses on developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients health care providers or payers. It operates in the research and development of diagnostic tests for the detection of cancer segment. For some indications it also focuses on pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It is working on diagnostic tests for three types of cancer: lung cancer breast cancer and bladder cancer.